Goldman Sachs’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.67M | Buy |
+20,000
| New | +$3.69M | ﹤0.01% | 3993 |
|
|
2023
Q3 | – | Sell |
-12,000
| Closed | -$3.42M | – | 5547 |
|
|
2023
Q2 | $3.42M | Buy |
12,000
+2,900
| +32% | +$863K | ﹤0.01% | 3434 |
|
|
2023
Q1 | $2.53M | Sell |
9,100
-56,500
| -86% | -$15.6M | ﹤0.01% | 3680 |
|
|
2022
Q4 | $18.2M | Buy |
65,600
+27,500
| +72% | +$7.77M | ﹤0.01% | 2052 |
|
|
2022
Q3 | $10.2M | Buy |
38,100
+10,000
| +36% | +$2.12M | ﹤0.01% | 2482 |
|
|
2022
Q2 | $5.73M | Hold |
28,100
| – | – | ﹤0.01% | 3005 |
|
|
2022
Q1 | $5.92M | Buy |
28,100
+8,100
| +41% | +$1.76M | ﹤0.01% | 3201 |
|
|
2021
Q4 | $4.8M | Sell |
20,000
-15,000
| -43% | -$3.86M | ﹤0.01% | 3451 |
|
|
2021
Q3 | $9.9M | Sell |
35,000
-15,000
| -30% | -$4.92M | ﹤0.01% | 2737 |
|
|
2021
Q2 | $17.3M | Buy |
50,000
+30,000
| +150% | +$9.09M | ﹤0.01% | 2179 |
|
|
2021
Q1 | $5.59M | Sell |
20,000
-42,900
| -68% | -$11.6M | ﹤0.01% | 3029 |
|
|
2020
Q4 | $15.4M | Buy |
62,900
+55,000
| +696% | +$14.2M | ﹤0.01% | 2074 |
|
|
2020
Q3 | $2.24M | Buy |
+7,900
| New | +$2.2M | ﹤0.01% | 3481 |
|
|
2020
Q2 | – | Sell |
-36,400
| Closed | -$11.5M | – | 5209 |
|
|
2020
Q1 | $11.5M | Buy |
36,400
+28,700
| +373% | +$8.71M | ﹤0.01% | 1982 |
|
|
2019
Q4 | $2.29M | Sell |
7,700
-5,100
| -40% | -$1.42M | ﹤0.01% | 3546 |
|
|
2019
Q3 | $2.98M | Sell |
12,800
-1,900
| -13% | -$442K | ﹤0.01% | 3245 |
|
|
2019
Q2 | $3.44M | Sell |
14,700
-2,100
| -13% | -$485K | ﹤0.01% | 3133 |
|
|
2019
Q1 | $3.97M | Sell |
16,800
-66,000
| -80% | -$20.8M | ﹤0.01% | 3163 |
|
|
2018
Q4 | $24.9M | Sell |
82,800
-1,700
| -2% | -$543K | 0.01% | 1614 |
|
|
2018
Q3 | $29.9M | Buy |
84,500
+15,900
| +23% | +$5.47M | 0.01% | 1614 |
|
|
2018
Q2 | $19.9M | Sell |
68,600
-24,400
| -26% | -$6.86M | 0.01% | 1876 |
|
|
2018
Q1 | $25.5M | Sell |
93,000
-12,300
| -12% | -$3.82M | 0.01% | 1649 |
|
|
2017
Q4 | $33.5M | Buy |
105,300
+6,900
| +7% | +$2.21M | 0.01% | 1571 |
|
|
2017
Q3 | $30.8M | Buy |
98,400
+28,900
| +42% | +$8.56M | 0.01% | 1648 |
|
|
2017
Q2 | $18.9M | Sell |
69,500
-27,200
| -28% | -$7.19M | ﹤0.01% | 1984 |
|
|
2017
Q1 | $26.4M | Sell |
96,700
-148,900
| -61% | -$42.1M | 0.01% | 1707 |
|
|
2016
Q4 | $69.6M | Buy |
245,600
+600
| +0.2% | +$178K | 0.02% | 1025 |
|
|
2016
Q3 | $76.7M | Buy |
245,000
+82,000
| +50% | +$24.3M | 0.02% | 890 |
|
|
2016
Q2 | $39.4M | Sell |
163,000
-67,100
| -29% | -$17.7M | 0.01% | 1294 |
|
|
2016
Q1 | $59.9M | Buy |
230,100
+8,900
| +4% | +$2.35M | 0.02% | 964 |
|
|
2015
Q4 | $67.8M | Sell |
221,200
-84,700
| -28% | -$24.3M | 0.02% | 909 |
|
|
2015
Q3 | $89.3M | Buy |
305,900
+141,900
| +87% | +$46.9M | 0.03% | 684 |
|
|
2015
Q2 | $66.2M | Sell |
164,000
-160,200
| -49% | -$64.3M | 0.02% | 914 |
|
|
2015
Q1 | $137M | Buy |
324,200
+100,400
| +45% | +$39.6M | 0.04% | 502 |
|
|
2014
Q4 | $76M | Buy |
223,800
+72,600
| +48% | +$23.5M | 0.02% | 830 |
|
|
2014
Q3 | $50M | Sell |
151,200
-14,600
| -9% | -$4.81M | 0.02% | 1068 |
|
|
2014
Q2 | $52.3M | Sell |
165,800
-17,600
| -10% | -$5.3M | 0.02% | 1067 |
|
|
2014
Q1 | $56.1M | Buy |
183,400
+96,500
| +111% | +$30.6M | 0.02% | 979 |
|
|
2013
Q4 | $24.3M | Sell |
86,900
-11,700
| -12% | -$3.03M | 0.01% | 1583 |
|
|
2013
Q3 | $23.7M | Sell |
98,600
-84,200
| -46% | -$18.8M | 0.01% | 1486 |
|
|
2013
Q2 | $39.3M | Buy |
+182,800
| New | +$39.1M | 0.02% | 1049 |
|
Other funds holding BIIB
VCM
VPM
Goldman Sachs's BIIB Position: Q1 2026 in Review
Goldman Sachs reduced its Biogen (BIIB) stake by 4.4% in Q1 2026, selling an estimated $8.89M and leaving 1,051,094 shares worth $193M. The position accounts for 0.02% of the portfolio, ranked #691.
Goldman Sachs first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $800M in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Goldman Sachs held 1,051,094 shares of Biogen worth $193M as of Q1 2026.
- Goldman Sachs sold 48,272 Biogen shares in Q1 2026, an estimated $8.89M.
- Biogen made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #691 holding.
- Goldman Sachs first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Biogen position peaked at $800M in Q3 2018.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.